NEW YORK (GenomeWeb News) – A shareholder is suing Sequenom and its board, alleging they breached their fiduciary duty and damaged the company by implementing an illegal strategy to drive up orders of the MaterniT21 Plus non-invasive prenatal diagnostic test.

The lawsuit was filed on Sept. 30 in the US District Court for the Southern District of California by Bette Borenstein derivatively on behalf of Sequenom, who also is a nominal defendant.

Through a spokesperson, Sequenom said that it does not comment on ongoing legal actions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.